

Cover Story
Conversation with The Cancer LetterFree
A year after starting his job as NCI director, Ned Sharpless is reviewing the entire spectrum of NCI research in an effort to focus on areas where the institute plays a key role.
In Brief


Clinical Roundup
Drugs & Targets


Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Peter F. Garrett to people with cancer: Your story has power
- What NHS-Galleri taught us—and what it didn’t
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”














